Publications

Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults

Vaccine. 2018 May 3;36(19):2604-2611
Hyer R, McGuire DK, Xing B, Jackson S, Janssen R.

Development of the CpG Adjuvant 1018: A Case Study

Vaccine Adjuvants (Methods Mol Biol.) 2017;1494:15-27
Campbell JD

Immunogenicity of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in subpopulations of healthy adults 18-70 years of age.

Vaccine. 2015 Jul 17;33(31):3614-8.
Janssen JM, Jackson S, Heyward WL, Janssen RS.

Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus.

Vaccine. 2015 Feb 11;33(7):833-7
Janssen JM, Heyward WL, Martin JT, Janssen RS.

Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults

Vaccine. 2018 May 3;36(19):2604-2611
Hyer R, McGuire DK, Xing B, Jackson S, Janssen R.

Development of the CpG Adjuvant 1018: A Case Study

Vaccine Adjuvants (Methods Mol Biol.) 2017;1494:15-27
Campbell JD

Immunogenicity of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in subpopulations of healthy adults 18-70 years of age.

Vaccine. 2015 Jul 17;33(31):3614-8.
Janssen JM, Jackson S, Heyward WL, Janssen RS.

Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus.

Vaccine. 2015 Feb 11;33(7):833-7
Janssen JM, Heyward WL, Martin JT, Janssen RS.

Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease.

Vaccine. 2013 Nov 4;31(46):5306-13.
Janssen RS, Mangoo-Karim R, Pergola PE, Girndt M, Namini H, Rahman S, Bennett SR, Heyward WL, Martin JT.

Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40–70 years of age.

Vaccine. 2013 Nov 4;31(46):5300-5.
Heyward WL, Kyle M, Blumenau J, Davis M, Reisinger K, Kabongo ML, Bennett S, Janssen RS, Namini H, Martin JT.

Safety and immunogenicity of different two-dose regimens of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in healthy young adults.

Vaccine, 2012; 30(36):5445-5448.
Scott A. Halperin, Shelly McNeil, Joanne M. Langley, Bruce Smith, Donna MacKinnon-Cameron, Robyn McCall-Sani, William L. Heyward, J. Tyler Martin.

Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of age.

Vaccine, 2012; 30(15): 2556-2563.
Scott A. Halperin, Brian Ward, et al.

Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine.

Vaccine, 2012; 30(16): 2689-2696.
Benjamin P. Sablan, Dong Joon Kim et al

Optimization, Production, and Characterization of a CpGOligonucleotide-Ficoll Conjugate Nanoparticle Adjuvant for Enhanced Immunogenicity of Anthrax Protective Antigen

Bioconjugate Chemistry, 2016, 27, 1293−1304, DOI: 10.1021/acs.bioconjchem.6b00107
Bob Milley, Radwan Kiwan, Gary S. Ott, Carlo Calacsan, Melissa Kachura, John D. Campbell, Holger Kanzler, and Robert L. Coffman

A CpG-Ficoll Nanoparticle Adjuvant for Anthrax Protective Antigen Enhances Immunogenicity and Provides Single-Immunization Protection against Inhaled Anthrax in Monkeys

The Journal of Immunology, 2016; 196:284-297; Prepublished online 25 November 2015; doi: 10.4049/jimmunol.1501903
Melissa A. Kachura, Colin Hickle et al.

Assessing the safety of adjuvanted vaccines.

Sci. Transl. Med., 2011; 3(93):93rv2.
Ahmed SS, Plotkin SA, Black S, Coffman RL.

Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response.

Immunity, 2011; 34(3):375-384.
Hou B, Saudan P, Ott G, Wheeler ML, Ji M, Kuzmich L, Lee LM, Coffman RL, Bachmann MF, DeFranco AL.

Vaccine adjuvants: putting innate immunity to work.

Immunity, 2010; 33(4):492-503.
Coffman, RL, Sher A, Seder RA.

CpG-containing immunostimulatory DNA sequences elicit TNF-α–dependent toxicity in rodents but not in humans.

J. Clin. Invest., 2009; 119(9):2564–2576.
John D. Campbell, Yan Cho, et al.

Signalling pathways leading to IFN-a production in human PDC and the possible use of agonists or antagonists of TLR-7 and TLR-9 in clinical indications (Review).

J. Intern. Med., 2009; 265:43-57.
Guiducci C, Coffman RL, Barrat FJ (Dynavax Technologies Corporation, Berkeley, CA USA).

Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists.

Nature Medicine, 2007; 13(5):552-559.
Holger Kanzler, Franck J Barrat, Edith M Hessel & Robert L Coffman.

Toll-like Receptor Recognition Regulates Immunodominance in an Antimicrobial CD4+ T Cell Response.

Immunity, 2006; 25:665-664.
Felix Yarovinsky, Holger Kanzler, Sara Hieny, Robert L. Coffman, and Alan Sher.

Properties Regulating the Nature of the Plasmacytoid Dendritic Cell Response to TLR9 Activation.

J. Exp. Med., 2006; 203(8):1999-2008.
Cristiana Guiducci, Gary Ott, Jean H. Chan, Emily Damon, Carlo Calacsan, Tracy Matray, Kyung-Dall Lee, Robert L. Coffman and Franck J. Barrat.

Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults.

Vaccine, 2006; 24(1): 20-26.
Scott A. Halperin, Simon Dobson et al.

Superior Activity of the Type C Class of ISS In Vitro and In Vivo Across Multiple Species.

DNA Cell Biol., 2005; 24(2):63-72.
Marshall, J.D., K.L. Fearon, et al.

CpG-C immunostimulatory oligodeoxyribonucleotide activation of plasmacytoid dendritic cells in rhesus macaques to augment the activation of IFN-gamma-secreting simian immunodeficiency virus-specific T cells.

J. Immunol., 2004; 173(3):1647-1657.
Teleshova, N., J. Kenney, J. Jones, J. Marshall, G. Van Nest, J. Dufour, R. Bohm, J.D. Lifson, A. Gettie, and M. Pope.

Polymyxin B enhances ISS-mediated immune responses across multiple species.

Cell. Immunol., 2004; 229(2):93-105.
Marshall, J.D., D. Higgins, C. Abbate, P. Yee, G. Teshima, G. Ott, T. Dela Cruz, D. Passmore, K.L. Fearon, S. Tuck, and G. Van Nest.